Company news

BioRestorative Therapies, Inc. news in 2023

BioRestorative Therapies, Inc.'s news releases, calls and decks from 2023, newest first.

View company

BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program

December 11, 2023

BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics

September 11, 2023

BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease

September 7, 2023

BioRestorative Therapies (NASDAQ: BRTX) Receives Landmark License From New York State

July 20, 2023

BioRestorative Therapies Announces $2.1 Million Registered Direct Offering

July 10, 2023

BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities

July 6, 2023

BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes

June 26, 2023

BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease

June 11, 2023

BioRestorative Therapies Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell Processing

May 30, 2023

BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program

May 14, 2023

BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company’s Phase 2 Clinical Trial

May 7, 2023

BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100

April 23, 2023

BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100

March 12, 2023

BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program

March 1, 2023

BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes

February 9, 2023

BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program

February 7, 2023

Decks in 2023